Arvinas’ (ARVN) “Buy” Rating Reaffirmed at Guggenheim

Guggenheim reiterated their buy rating on shares of Arvinas (NASDAQ:ARVN) in a report issued on Wednesday morning,Benzinga reports. The firm currently has a $57.00 target price on the stock.

A number of other research firms also recently weighed in on ARVN. Wedbush reissued an “outperform” rating and set a $57.00 target price on shares of Arvinas in a research report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a research report on Friday, February 7th. Stephens began coverage on shares of Arvinas in a research note on Monday, November 18th. They set an “overweight” rating and a $55.00 target price for the company. Stifel Nicolaus cut their price target on shares of Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, BMO Capital Markets lowered their price objective on Arvinas from $90.00 to $88.00 and set an “outperform” rating for the company in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $59.58.

Arvinas Stock Up 1.5 %

Shares of Arvinas stock opened at $17.95 on Wednesday. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of -3.84 and a beta of 1.88. Arvinas has a twelve month low of $16.61 and a twelve month high of $53.08. The company’s fifty day moving average is $19.18 and its 200 day moving average is $23.32.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. During the same period in the prior year, the business posted ($2.53) earnings per share. As a group, equities analysts anticipate that Arvinas will post -3.22 earnings per share for the current fiscal year.

Institutional Trading of Arvinas

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARVN. JPMorgan Chase & Co. boosted its holdings in Arvinas by 18.7% in the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock worth $57,371,000 after acquiring an additional 367,343 shares in the last quarter. Baker BROS. Advisors LP acquired a new position in shares of Arvinas during the third quarter worth approximately $9,989,000. SG Americas Securities LLC lifted its holdings in shares of Arvinas by 228.8% in the 4th quarter. SG Americas Securities LLC now owns 32,424 shares of the company’s stock worth $622,000 after purchasing an additional 22,564 shares in the last quarter. Wasatch Advisors LP grew its position in Arvinas by 58.3% in the 3rd quarter. Wasatch Advisors LP now owns 435,943 shares of the company’s stock valued at $10,737,000 after purchasing an additional 160,510 shares during the period. Finally, Barclays PLC grew its position in Arvinas by 198.9% in the 3rd quarter. Barclays PLC now owns 121,699 shares of the company’s stock valued at $2,998,000 after purchasing an additional 80,984 shares during the period. 95.19% of the stock is owned by institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.